Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.
Currently, the organization relies on a mobile PET unit that parks once every week. However, demand has grown for PET/CT in the area, rising by around 60% over the last three years alone.
Limbic-predominant age-related TDP-43 encephalopathy, also known as LATE, was recently recognized as a type of dementia that occurs in older adults. It typically presents as memory-related cognitive decline.
Amyloid-related imaging abnormality edema is a known side effect of anti-amyloid monoclonal antibody treatments, such as Leqembi and donanemab Kisunla.
A study published in the January issue of the Journal of Nuclear Medicine reveals that nearly half of Medicare patients with NSCLC in the United States do not complete recommended FDG PET/CT scans prior to treatment.
Primary aldosteronism (PA) is one the single most common causes of hypertension, but identifying patients with PA—and knowing which ones may benefit from a surgical treatment—can be quite challenging.
The 10-minute scan can “light up” aldosterone-producing nodules in the adrenal glands following an injection of metomidate—a radioactive dye that binds specifically to aldosterone-producing nodules.
Prior to the Dec. 15 announcement, CMS had released a different statement in June informing the public that they were reconsidering the amount of PET scans that Alzheimer’s patients undergoing monoclonal antibody treatment can receive.
The radiotracer, 68Ga-PentixaFor, can be used for detecting C-X-C motif chemokine receptor 4 (CXCR4), which plays a significant role in cancer progression.
Common markers of Alzheimer's disease visualized on PET scans of asymptomatic patients might foreshadow the onset of symptoms in the years following their initial discovery.